In three patients with Alzheimer’s disease, focused ultrasound was applied with aducanumab therapy. Reduction in amyloid was greater in treated regions than in matched contralateral regions over 6 months. Read the full report:

Original Article from The New England Journal of Medicine — Ultrasound Blood–Brain Barrier Opening and Aducanumab in Alzheimer’s Disease.